MILWAUKEE, March 06, 2026 (GLOBE NEWSWIRE) — Enerpac Tool Group Corp. (NYSE: EPAC) announced today that it will release its second quarter fiscal 2026 earnings after the market closes on Wednesday, March 25, 2026. Management will conduct a conference call to discuss the results on Thursday, March 26, 2026, beginning at 8:30 a.m. ET / 7:30 a.m. CT. A real-time webcast of the conference call can be accessed via the Investors section of the Company’s website. For those who are unavailable to listen to the live broadcast, a replay will be available shortly after the call for 90 days. About Enerpac Tool Group Enerpac Tool Group Corp. is a premier industrial tools, services, technology, and solutions provider serving a broad and diverse set of customers and end markets for mission-critical applications in more than 100 countries. The...

ATHENS, Greece, March 06, 2026 (GLOBE NEWSWIRE) — IMPERIAL PETROLEUM INC. (NASDAQ: IMPP; the “Company”), a ship-owning company providing petroleum products, crude oil and dry bulk seaborne transportation services, announced today its unaudited financial and operating results for the fourth quarter and twelve months ended December 31, 2025. OPERATIONAL AND FINANCIAL HIGHLIGHTSFleet operational utilization of 91.8% for Q4 25’ compared to 88.7% in Q3 25’, representing the best quarterly performance in 2025. In Q4 24’ our fleet operational utilization was 86.0%. Fleet operational utilization for Q4 25’ was 90.4% for our drybulk fleet and 93.4% for our tanker fleet. Reduction of idle days in Q4 25’ by 24.3% compared to Q3 25’. About 71% of total fleet calendar days in Q4 25’ were dedicated to time charter activity while 29% to spot...

200% Q-O-Q increase in net income to $58 million in Q4 2025  $800 million of gross revenues and $161 million of net income for 2025 ($4.45 per share) $416 million in adj. EBITDA in 2025 TEN benefitting from historical high tanker rates. Timely NB orders of LNG & VLCCs $4 billion in Minimum Contracted Revenue ATHENS, Greece, March 06, 2026 (GLOBE NEWSWIRE) — TEN, Ltd (TEN) (NYSE: TEN) (the “Company”) today reported results (unaudited) for the twelve months and fourth quarter ended December 31, 2025. TWELVE MONTHS 2025 SUMMARY RESULTSTEN’s fleet for the twelve months of 2025, generated close to $800 million in gross revenues, and approx. $252 million in operating income inclusive of $12.5 million in capital gains from the sale of four older vessels. Net income for the twelve months of 2025 was $161 million or $4.45 per share. Adjusted...

– 64% overall survival observed at 12 months in ongoing Phase 2a trial of atebimetinib + mGnP in first-line pancreatic cancer patients, well above the standard of care benchmark from GnP of 35% overall survival;On track for expanded pancreatic cancer cohort data readout in first half of 2026 – – On track to dose first patient in pivotal Phase 3 MAPKeeper 301 trial of atebimetinib + mGnP in patients with first-line metastatic pancreatic cancer in mid-2026 – – Dosing in Phase 2 trial of atebimetinib + Libtayo® in patients with first-line RAS-mutant non-small cell lung cancer expected to begin in second half of 2026 – – Ended 2025 with $217 million in cash, cash equivalents and marketable securities with anticipated runway into 2029 – NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) — Immuneering...

Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression remains on track for Q2 2026 following successful End‑of‑Phase 2 meeting with the U.S. Food and Drug Administration On-track for VLS-01 Phase 2 Elumina trial topline data readout anticipated in H2 2026 Exploratory Phase 2a trial of EMP-01 in Social Anxiety Disorder met its primary safety and tolerability objective and demonstrated clinically meaningful improvements across key efficacy measures Cash runway through the planned early-2029 topline readouts from both Phase 3 pivotal studies Virtual Investor Day scheduled for March 6, 2026NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) — AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or the “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting,...

JADE101 Phase 1 healthy volunteer interim data expected in the second quarter of 2026; Phase 2 clinical trial in patients with IgA nephropathy expected to begin mid-2026 with preliminary data anticipated in 2027 JADE201, a half-life extended afucosylated anti-BAFF receptor antibody, expected to advance into first-in-human clinical trial in rheumatoid arthritis patients in the second quarter of 2026; interim data anticipated in 2027 Third development candidate, JADE301, nominated; Phase 1 clinical trial expected to commence in the first half of 2027 $336 million of cash, cash equivalents, and investments as of December 31st, 2025 expected to provide runway into the first half of 2028SAN FRANCISCO and VANCOUVER, British Columbia, March 06, 2026 (GLOBE NEWSWIRE) — Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO),...

Press Release Full Year 2025 Results:Atos Group has Delivered on its Commitments to Restore its Foundations Growth Chapter Ready to be OpenedFY 2025 financial and extra financial targets met or exceeded:Revenue at €8,001 million, reflecting a clear improvement in the organic growth trajectory in Q4 Operating margin at €351 million, representing 4.4% of revenue, doubling year-on-year Net change in cash1 limited to €-326 million despite faster than expected execution of the restructuring program Greenhouse gas emissions reduced by 58% compared with the 2019 baseline.Execution of Genesis strategic and transformation plan ahead of schedule, with 88%2 of the three-year savings target completed in less than one year Strengthened commercial traction, with early signs of renewed client confidence Scaling artificial intelligence (AI) from...

High-quality performance with outstanding cash generation Upgraded mid-term margin target Governance evolution, ensuring smooth transition and full strategic continuityCergy, March 6th, 2026 Record profitability and solid revenue growth, pushing revenue well above the €10 bn markRevenue: €10,380 million, up +4.8% vs. 2024, including +3.2% growth from acquisitions and +2.0% organic growth, with Germany confirmed as the Group’s primary growth driver (+5.3%), well supported by North-Western Europe (+4.3%) EBITA increased sharply by 11.4% to €793 million, with the margin reaching a record 7.6% (+40 bps), driven by pricing power, selectivity, operational excellence and accretive acquisitions Adjusted net income1:  €458 million (+9% vs. 2024) Recommended dividend: €1.08 per share2, up 8%  Another year of outstanding free cash flow€524...

Transitioned to a pure-play industrial REIT; Attractive development properties completed; Strong leasing activity TORONTO, March 05, 2026 (GLOBE NEWSWIRE) — Nexus Industrial REIT (the “REIT”) (TSX: NXR.UN) announced today its results for the fourth quarter and year ended December 31, 2025. “2025 was a transformative year for Nexus, and I am very pleased with the results” said Kelly Hanczyk, CEO of Nexus Industrial REIT. We kept a long-term focus, completing our strategic transition to become the only scale, Canada-focused industrial REIT, and completed two value-accretive projects, adding 440,000 square feet of GLA that will deliver an unlevered return of 9.4% on development costs. We also acquired two well-located, high-quality buildings in Montreal initially contributing $2.6 million in annual NOI with significant mark-to-market...

CALGARY, Alberta, March 05, 2026 (GLOBE NEWSWIRE) — Badger Infrastructure Solutions Ltd. (“Badger”, the “Company”, “we”, “our” or “us”) (TSX:BDGI) reported fourth quarter and 2025 annual results today. All results are presented in U.S. dollars unless otherwise stated. 2025 FOURTH QUARTER AND ANNUAL FINANCIAL AND OPERATIONAL HIGHLIGHTSThe Company achieved revenue of $213.5 million for the quarter and $831.7 million for the year, up 14% and 12%, respectively, from 2024. Adjusted EBITDA(1) improved to $44.9 million for the quarter and $198.2 million for the year, up 2% and 13%, respectively, from 2024. Adjusted net earnings per share(1) was $0.34 per share for the quarter and improved to $2.04 per share for the year, up 21% from 2024. Revenue per truck per month (“RPT”)(1) for the quarter and the year was $41,756 and $41,672, respectively,...